Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists stalk PPAR-gamma, find novel cancer connection

08.12.2004


Research shows existing diabetes drugs may kill multiple myeloma



In laboratory tests on multiple myeloma cells, University of Rochester researchers found that this type of cancer expresses a protein that makes it an easy target for an existing class of diabetes drugs. After more investigation, they hope the discovery will lead to a new, targeted therapy for myeloma patients. "To our knowledge, this is the first time anyone has shown that multiple myeloma cells are sensitive to these agents, and we found multiple myeloma cells are killed quite effectively," says lead author Richard P. Phipps, Ph.D., professor of Environmental Medicine and of Oncology at the University of Rochester Medical Center.

The research was reported in the November issue of Clinical Immunology.


The drugs in question are from the thiazolidinedione (TZD) class of anti-diabetic therapies, known as PPAR-gamma ligands. They bind to PPAR-gamma, a protein associated with multiple myeloma and many other cancers, as well as chronic inflammation and diabetes. When the drugs bind to PPAR-gamma, at least in laboratory experiments, the cancerous cells are destroyed.

PPAR-ligands are emerging as a new type of cancer therapy because they directly target errant cells and stop tumor growth, at least in animal models. Phipps’ laboratory also found that the PPAR-ligands currently used in anti-diabetic drugs could induce a type of cell death called apoptosis. This is significant because multiple myeloma is very difficult to treat, as it is usually resistant to drug-induced apoptosis.

Another encouraging factor is that the anti-diabetes drugs were able to kill the multiple myeloma cells, despite the fact that myeloma produces its own growth factor (Interleukin 6), which usually enables the cancer to multiply more effectively. Furthermore, the Phipps lab found that the effectiveness of the TZD drugs was enhanced when combined with Vitamin A-like compounds.

Co-investigator Steven Bernstein, M.D., who treats myeloma patients at the University’s James P. Wilmot Cancer Center, is cautious but hopeful about the prospects of this research leading to a new treatment. "Although we are optimistic about these early findings, we need to do further investigation to understand how the TZD class of drugs work against multiple myeloma, before clinical trials are warranted."

Each year doctors diagnose about 14,000 people in the United States with multiple myeloma, which accounts for about 10 percent of the blood cancers. Myeloma is characterized by an abnormal number of white blood cells called plasma cells. They crowd out healthy blood cells in the bone marrow, and make proteins that lead to bone destruction, kidney damage, and recurrent infections.

High-dose chemotherapy and stem-cell transplant are the standard treatments. Recently, patients have also experienced some success with two new, biologically targeted therapies: thalidomide, which was given decades ago to women for morning sickness, and the proteosome inhibitor Velcade, which targets the parts of the cell that regulates protein expression, Bernstein said. The latest research may offer a third novel approach.

The myeloma research emerged from a larger investigation conducted by Phipps’ laboratory into inflammation, the culprit of many serious illnesses. One area of focus is how the immune system reacts to PPAR-ligands.

Leslie Orr | EurekAlert!
Further information:
http://www.rochester.edu

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>